Evidence map›Paper›PMID 28823024›Full record

ArticleJournal of natural medicines2018

Effect of Kaempferia parviflora extract on knee osteoarthritis.

Hiroko Kobayashi, Ryo Suzuki, Kei Sato, Takatoshi Ogami, Hiroshi Tomozawa, Masahito Tsubata, Koji Ichinose, Masaki Aburada, Wataru Ochiai, Kiyoshi Sugiyama and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Nutrients · 2023
    Article
  6. The industrially important genusFrontiers in pharmacology · 2023
    Review
  7. Molecules (Basel, Switzerland) · 2021
    Article
  8. Recent Advances inNutrients · 2019
    Review
  9. Article
  10. Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hiroko KobayashiGraduate School of Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa, Tokyo, 142-8501, Japan.
Ryo SuzukiFaculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo, 202-8585, Japan.
Kei SatoResearch and Development Division, Toyo Shinyaku Co., Ltd., 7-28 Yayoigaoka, Tosu-shi, Saga, 841-0005, Japan.
Takatoshi OgamiResearch and Development Division, Toyo Shinyaku Co., Ltd., 7-28 Yayoigaoka, Tosu-shi, Saga, 841-0005, Japan.
Hiroshi TomozawaResearch and Development Division, Toyo Shinyaku Co., Ltd., 7-28 Yayoigaoka, Tosu-shi, Saga, 841-0005, Japan.
Masahito TsubataResearch and Development Division, Toyo Shinyaku Co., Ltd., 7-28 Yayoigaoka, Tosu-shi, Saga, 841-0005, Japan.
Koji IchinoseFaculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo, 202-8585, Japan.
Masaki AburadaFaculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo, 202-8585, Japan.
Wataru OchiaiGraduate School of Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa, Tokyo, 142-8501, Japan.
Kiyoshi SugiyamaGraduate School of Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa, Tokyo, 142-8501, Japan.
Tsutomu ShimadaDepartment of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. t-shimada@staff.kanazawa-u.ac.jp.
Nippon Shinyaku (Japan) · JPMusashino University · JPHoshi University · JPEbara (Japan) · JPKanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knee osteoarthritis (OA) is becoming more prevalent worldwide due to increases in the numbers of elderly and obese patients. Currently, pharmaceutical medicines used for the treatment of OA are for symptomatic therapy and therefore new therapeutic agents are needed. Kaempferia parviflora (KP) is a plant growing naturally in Southeast Asia and has various pharmacological effects including an anti-inflammatory effect, but no effect on OA has yet been reported. We therefore conducted a search for the effects KP and the active components of KP extract (KPE) exert on OA as well as its mechanism of action. Results from a study of KPE using the monoiodoacetic acid rat OA model revealed that KPE reduced the pain threshold and severity of osteoarthritic cartilage lesions. The mechanism of action and active components were then investigated using IL-1β-treated human knee-derived chondrocytes. KPE, as well as 5,7-dimethoxyflavone and 5,7,4'-trimethoxyflavone, which are key constituents of KPE and highly absorbable into the body, reduced the expression of matrix metalloproteinases (MMPs), which are the main extracellular matrix enzymes that degrade collagen within cartilage. As mentioned above, KPE acted to suppress OA and 5,7-dimethoxyflavone and 5,7,4'-trimethoxyflavone were shown to be involved as part of KPE's mechanism that inhibits MMPs.

Indexed as

AnimalsHumansMaleOsteoarthritis, KneeRatsRats, WistarZingiberaceaeKaempferia parvifloraMatrix metalloproteinasesOsteoarthritisPolymethoxyflavonoids

Identifiers

PMID28823024
OpenAlexW2748992572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.